AbbVie reported 10.2% operational revenue growth to nearly $17 billion, driven by Skyrizi at $5.5 billion (24% growth) and Rinvoq at $2.5 billion (23.7% growth), alongside neuroscience reaching $3.2 billion (20% growth). Offsetting factors included a 0.7% EPS miss, Humira's 36% decline to $706 million, and a 0.9% drop in aesthetics revenue. Management raised Rinvoq peak sales estimates and highlighted the Apogee acquisition for future pipeline strength, projecting sustained long-term growth despite competitive pressures and organic gaps.

Company: AbbVie Inc. (ABBV) — Q2 FY2026

🎙️ Want podcasts like this on any of 5,000+ companies? Podfolio turns earnings calls, filings, and market data into short, listenable briefings — and builds a bespoke daily podcast around your own portfolio and watchlist. Your holdings, your companies, your com ...